Literature DB >> 380853

Research in leprosy. A report of a committee set up by the medical research council to study future prospects.

.   

Abstract

Recommendations for future research in leprosy include (i) cultivation of M. leprae in vitro; (ii) genetic control of susceptibility, including twin studies and HLA typing; (iii) precise antigenic analysis of M. leprae; (iv) mechanisms involved in the macrophage response to mycobacterial infections; (v) more use of experimental models such as normal mice infected with M. lepraemurium; (vi) reassessment of the protection afforded by BCG; (vii) assessment of protection afforded by killed (armadillo) M. leprae vaccine; (viii) pathogenesis of erythema nodosum leprosum including a study of the effect of thalidomide; and (ix) development of in vitro systems for drug sensitivity testing.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 380853      PMCID: PMC1537685     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Immune complexes and complement hypercatabolism in patients with leprosy.

Authors:  B Bjorvatn; R S Barnetson; G Kronvall; R H Zubler; P H Lambert
Journal:  Clin Exp Immunol       Date:  1976-12       Impact factor: 4.330

2.  Autoradiographic and metabolic studies of Mycobacterium leprae.

Authors:  S R Khanolkar; E J Ambrose; R G Chulawala; C V Bapat
Journal:  Lepr Rev       Date:  1978-09       Impact factor: 0.537

3.  Primary dapsone-resistant leprosy.

Authors:  J M Pearson; G S Haile; R J Rees
Journal:  Lepr Rev       Date:  1977-06       Impact factor: 0.537

4.  The nasal dicharge in leprosy: clinical and bacteriological aspects.

Authors:  T F Davey; R J Rees
Journal:  Lepr Rev       Date:  1974-06       Impact factor: 0.537

5.  Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli.

Authors:  M F Waters; R J Rees; A C McDougall; A G Weddell
Journal:  Lepr Rev       Date:  1974-12       Impact factor: 0.537

6.  Airborne infection with Mycobacterium leprae in mice.

Authors:  R J Rees; A C McDougall
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

7.  Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions.

Authors:  G Bjune; R S Barnetson; D S Ridley; G Kronvall
Journal:  Clin Exp Immunol       Date:  1976-07       Impact factor: 4.330

8.  Antibodies against BCG antigen 60 in mycobacterial infection.

Authors:  M Harboe; O Closs; B Bjorvatn; G Bjune
Journal:  Br Med J       Date:  1977-08-13

9.  Heat stability of Mycobacterium leprae immunogenicity.

Authors:  C C Shepard; L L Walker; R van Landingham
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

10.  In-vitro lymphoproliferative response to Mycobacterium leprae of HLA-D-identical siblings of lepromatous leprosy patients.

Authors:  G L Stoner; J Touw; A Belehu; B Naafs
Journal:  Lancet       Date:  1978-09-09       Impact factor: 79.321

View more
  4 in total

1.  Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

2.  SDS-PAGE analysis of M. leprae protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos.

Authors:  A K Chakrabarty; M A Maire; P H Lambert
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

3.  Immunochemical characterization of Mycobacterium leprae antigens by the SDS-polyacrylamide gel electrophoresis immunoperoxidase technique (SGIP) using patients' sera.

Authors:  P R Klatser; M M van Rens; T A Eggelte
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

4.  BCG, Corynebacterium parvum or Mycobacterium leprae added to cultures of BCG-primed mouse spleen cells cause an enhanced primary antibody response in vitro.

Authors:  C A Brown; I N Brown; V S Sljivić
Journal:  Immunology       Date:  1981-01       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.